Experts and Doctors on uterine cervical neoplasms in United States

Summary

Locale: United States
Topic: uterine cervical neoplasms

Top Publications

  1. Maruyama Y, van Nagell J, Yoneda J, Gallion H, DePriest P, Feola J, et al. Schedule in Cf-252 neutron brachytherapy: complications after delayed implant therapy for cervical cancer in a phase II trial. Am J Clin Oncol. 1993;16:168-74 pubmed
    ..The delayed Cf implant apparently contributed to the greater risk for normal tissue complications. ..
  2. Knowlton A, Brown H, Richards T, Andreolas L, Patel R, Grieshaber S. Chlamydia trachomatis infection causes mitotic spindle pole defects independently from its effects on centrosome amplification. Traffic. 2011;12:854-66 pubmed publisher
    ..We hypothesize that these combined effects on mitotic spindle architecture identifies a possible mechanism for Chlamydia as a cofactor in cervical cancer formation. ..
  3. Chung S, Shin M, Korach K, Lambert P. Requirement for stromal estrogen receptor alpha in cervical neoplasia. Horm Cancer. 2013;4:50-9 pubmed publisher
    ..This is the first evidence to support the importance of stromal ER? in estrogen-dependent neoplastic disease of the female reproductive tract. ..
  4. Ha G, Kim J, Breuer E, Breuer E. TACC3 is essential for EGF-mediated EMT in cervical cancer. PLoS ONE. 2013;8:e70353 pubmed publisher
    ..Collectively, our study highlights a novel function for TACC3 in EGF-mediated EMT process and suggests that targeting of TACC3 may be an attractive strategy to treat cervical cancers driven by EGF/EGFR signaling pathways. ..
  5. Lin Y, Fan L, Tu Y. Perceived Risk of Human Papillomavirus Infection and Cervical Cancer among Adolescent Women in Taiwan. Asian Nurs Res (Korean Soc Nurs Sci). 2016;10:45-50 pubmed publisher
    ..Appropriate education strategies should be developed and conducted by healthcare professionals to reduce the risk of cervical cancer threat from adolescence. ..
  6. Hawes S, Critchlow C, Faye Niang M, Diouf M, Diop A, Toure P, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis. 2003;188:555-63 pubmed
    ..Furthermore, HIV-2-positive women were more likely to have HSILs (OR, 3.3; 95% CI, 0.9-12.4) or ICC (OR, 7.9; 95% CI, 1.1-57) than were HIV-1-positive women. ..
  7. Brown D, Johnson F, Poulos C, Messonnier M. Mothers' preferences and willingness to pay for vaccinating daughters against human papillomavirus. Vaccine. 2010;28:1702-8 pubmed publisher
    ..These findings provide new data on how HPV vaccines are viewed and valued by mothers, and how uptake may change in the context of evolving vaccine technology and as new data are reported on duration and efficacy. ..
  8. Kunos C, Radivoyevitch T, Kresak A, Dawson D, JACOBBERGER J, Yang B, et al. Elevated ribonucleotide reductase levels associate with suppressed radiochemotherapy response in human cervical cancers. Int J Gynecol Cancer. 2012;22:1463-9 pubmed publisher
    ..Further validation testing of RNR subunits as biomarkers for radiochemotherapy response is warranted. ..
  9. Nieves L, Enerson C, Belinson S, Brainard J, Chiesa Vottero A, Nagore N, et al. Primary cervical cancer screening and triage using an mRNA human papillomavirus assay and visual inspection. Int J Gynecol Cancer. 2013;23:513-8 pubmed publisher
    ..Follow-up evaluation will be important to determine the true impact of potential undertreatment in the screening algorithm. Self-sampling applications are explored. ..

More Information

Publications160 found, 100 shown here

  1. Brooks S, Carter R, Plaxe S, Basen Engquist K, Rodriguez M, Kauderer J, et al. Patient and physician factors associated with participation in cervical and uterine cancer trials: an NRG/GOG247 study. Gynecol Oncol. 2015;138:101-8 pubmed publisher
    ..6; CI 1.6-8.4), and trial would not be time consuming (OR 3.3; CI 1.3-8.1). Trial availability, patient and physician beliefs were factors identified that if modified could improve enrollment in cancer cooperative group clinical trials. ..
  2. Xi L, Hughes J, Castle P, Edelstein Z, Wang C, Galloway D, et al. Viral load in the natural history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis. 2011;203:1425-33 pubmed publisher
    ..001). Viral load of newly detected infections and changes in viral load predict persistence and progression of HPV-16 infections. ..
  3. Einstein M, Rash J, Chappell R, Swietlik J, Hollenberg J, Connor J. Quality of life in cervical cancer survivors: patient and provider perspectives on common complications of cervical cancer and treatment. Gynecol Oncol. 2012;125:163-7 pubmed publisher
    ..Providers and survivors diverge on which complications impact QOL the most. Data on patient preferences should be considered when weighing treatment options with similar survival but different associated complications. ..
  4. Jin X, Lipold L, McKenzie M, Sikon A. Cervical cancer screening: what's new and what's coming?. Cleve Clin J Med. 2013;80:153-60 pubmed publisher
    ..We review these recommendations and the possible future direction of screening. ..
  5. Paskett E, Dudley D, Young G, Bernardo B, Wells K, Calhoun E, et al. Impact of Patient Navigation Interventions on Timely Diagnostic Follow Up for Abnormal Cervical Screening. J Womens Health (Larchmt). 2016;25:15-21 pubmed publisher
    ..No effect was observed among high-risk women. These results suggest that patient navigation can improve timely diagnostic follow-up among women with low-risk cervical abnormalities, particularly in non-English-speaking Hispanic women. ..
  6. Long H, Rayson S, Podratz K, Abu Ghazaleh S, Suman V, Hartmann L, et al. Long-term survival of patients with advanced/recurrent carcinoma of cervix and vagina after neoadjuvant treatment with methotrexate, vinblastine, doxorubicin, and cisplatin with or without the addition of molgramostim, and review of the literature. Am J Clin Oncol. 2002;25:547-51 pubmed
    ..Its progression-free survival and overall survival rates appear promising. These results need to be confirmed within a large randomized phase III clinical trial. ..
  7. Ferris D, Horn L, Waller J. Parental acceptance of a mandatory human papillomavirus (HPV) vaccination program. J Am Board Fam Med. 2010;23:220-9 pubmed publisher
    ..Greater education of parents and health care providers should improve vaccination uptake, which ultimately reduces morbidity and mortality from HPV related diseases. ..
  8. Kunos C, Radivoyevitch T, Abdul Karim F, Faulhaber P. 18F-fluoro-2-deoxy-D-glucose positron emission tomography standard uptake value ratio as an indicator of cervical cancer chemoradiation therapeutic response. Int J Gynecol Cancer. 2011;21:1117-23 pubmed publisher
    ..In patients with cervical cancer, the 3-month posttherapy F-FDG PET/CT value is an indicator of therapeutic response to chemoradiation and needs further validation in clinical trials. ..
  9. Crosby R, Casey B, Vanderpool R, Collins T, Moore G. Uptake of free HPV vaccination among young women: a comparison of rural versus urban rates. J Rural Health. 2011;27:380-4 pubmed publisher
    ..Moreover, uptake of subsequent free doses among rural women may be problematic regardless of whether contact is made in a clinic or through college recruitment. ..
  10. Levinson K, Abuelo C, Chyung E, Salmeron J, Belinson S, Sologuren C, et al. The Peru cervical cancer prevention study (PERCAPS): community-based participatory research in Manchay, Peru. Int J Gynecol Cancer. 2013;23:141-7 pubmed publisher
    ..These techniques may help overcome barriers to large-scale preventive health-care interventions. ..
  11. Kunos C, Radivoyevitch T, Waggoner S, Debernardo R, Zanotti K, Resnick K, et al. Radiochemotherapy plus 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, NSC #663249) in advanced-stage cervical and vaginal cancers. Gynecol Oncol. 2013;130:75-80 pubmed publisher
    ..Future randomized phase II and III clinical trials of 3-AP radiochemotherapy are warranted. ..
  12. Iezzoni L, Kurtz S, Rao S. Trends in Pap Testing Over Time for Women With and Without Chronic Disability. Am J Prev Med. 2016;50:210-9 pubmed publisher
    ..Little has changed over time in Pap test rates for all women. Women with certain disabilities continue to experience disparities compared with nondisabled women in receipt of this important screening test. ..
  13. Chan J, Deng W, Higgins R, Tewari K, Bonebrake A, Hicks M, et al. A phase II evaluation of brivanib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017;146:554-559 pubmed publisher
    ..Based on early results of this phase II trial, brivanib was well tolerated and demonstrated sufficient activity after first stage but trial was stopped due to lack of drug availability. ..
  14. Shondel S, Helm C, Gercel Taylor C, Taylor D. Differential expression of T-cell CD3-zeta chains in patients with cervical dysplasia before and after treatment. Int J Gynecol Cancer. 2007;17:1278-82 pubmed
    ..In vitro zeta expression increased in patients with CIN II and III after treatment, although the increase was only statistically significant in patients with CIN II. ..
  15. Salani R, Puri I, Bristow R. Adenocarcinoma in situ of the uterine cervix: a metaanalysis of 1278 patients evaluating the predictive value of conization margin status. Am J Obstet Gynecol. 2009;200:182.e1-5 pubmed publisher
    ..2%) compared with negative margins (0.1%). After conization for ACIS, patients with positive margins are significantly more likely to have residual or recurrent disease, whereas those with negative margins may be treated conservatively. ..
  16. Saraiya M, Unger E, Thompson T, Lynch C, Hernandez B, Lyu C, et al. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines. J Natl Cancer Inst. 2015;107:djv086 pubmed publisher
    ..In the United States, current vaccines will reduce most HPV-associated cancers; a smaller additional reduction would be contributed by the new 9-valent vaccine. ..
  17. DeSimone C, Day M, Tovar M, Dietrich C, Eastham M, Modesitt S. Rate of pathology from atypical glandular cell Pap tests classified by the Bethesda 2001 nomenclature. Obstet Gynecol. 2006;107:1285-91 pubmed
    ..Adherence to recommended AGC management guidelines is crucial to identify underlying malignancies. II-2. ..
  18. Brewer J, Benghuzzi H, Tucci M. Effects of thymoquinone, lycopene, and selenomethione in the presence of estrogen on the viability of SiHa cells in vitro. Biomed Sci Instrum. 2006;42:37-41 pubmed
  19. Carlson M, Iyer V, Marcotte E. Quantitative gene expression assessment identifies appropriate cell line models for individual cervical cancer pathways. BMC Genomics. 2007;8:117 pubmed
    ..This method is applicable to other cancers and could be used to identify the appropriate cell line and growth condition to employ when studying other cancers. ..
  20. Katz M, Reiter P, Heaner S, Ruffin M, Post D, Paskett E. Acceptance of the HPV vaccine among women, parents, community leaders, and healthcare providers in Ohio Appalachia. Vaccine. 2009;27:3945-52 pubmed publisher
    ..There are differences in HPV vaccine acceptability among different types of community members highlighting the need for a range of HPV vaccine educational materials/programs to be developed that are inclusive of the Appalachian culture. ..
  21. Jabbar S, Abrams L, Glick A, Lambert P. Persistence of high-grade cervical dysplasia and cervical cancer requires the continuous expression of the human papillomavirus type 16 E7 oncogene. Cancer Res. 2009;69:4407-14 pubmed publisher
    ..These results suggest that E7 is a relevant target not only for anticancer therapy but also for the treatment of HPV-positive dysplastic cervical lesions. ..
  22. Han P, Klabunde C, Breen N, Yuan G, Grauman A, Davis W, et al. Multiple clinical practice guidelines for breast and cervical cancer screening: perceptions of US primary care physicians. Med Care. 2011;49:139-48 pubmed publisher
    ..The number, aggressiveness, and agreement of valued guidelines are associated with screening recommendations, suggesting that guideline multiplicity is an important problem in clinical decision-making. ..
  23. Mills L, Vanderpool R, Crosby R. Sexually related behaviors as predictors of HPV vaccination among young rural women. J Womens Health (Larchmt). 2011;20:1909-15 pubmed publisher
  24. Gillison M, Castellsague X, Chaturvedi A, Goodman M, Snijders P, Tommasino M, et al. Eurogin Roadmap: comparative epidemiology of HPV infection and associated cancers of the head and neck and cervix. Int J Cancer. 2014;134:497-507 pubmed publisher
    ..Key research challenges include understanding oral HPV transmission and male predominance, clarifying the role of cofactors, and developing new screening and treatment methods for HPV-associated HNSCC. ..
  25. Yan M, Parker B, Schwab R, Kurzrock R. HER2 aberrations in cancer: implications for therapy. Cancer Treat Rev. 2014;40:770-80 pubmed publisher
    ..A large number of novel HER2-targeted agents are also in clinical trials. Herein we discuss the state of the art in understanding and targeting HER2 across anatomic tumor types. ..
  26. Rose P, Java J, Whitney C, Stehman F, Lanciano R, Thomas G. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol Oncol. 2014;135:208-12 pubmed publisher
  27. Wyss J, Carmona R, Karunamuni R, Pritz J, Hoh C, Mell L. [(18)F]Fluoro-2-deoxy-2-d-glucose versus 3'-deoxy-3'-[(18)F]fluorothymidine for defining hematopoietically active pelvic bone marrow in gynecologic patients. Radiother Oncol. 2016;118:72-8 pubmed publisher
    ..Within the limitations of a small sample size, we found significant agreement between FDG-PET and FLT-PET; however, FLT-PET had significantly less individual variation and is likely to be superior to FDG-PET for BM-sparing radiotherapy. ..
  28. McGrath C, Garcia R, Trinh T, Richardson B, John Stewart G, Nyongesa Malava E, et al. Role of p16 testing in cervical cancer screening among HIV-infected women. PLoS ONE. 2017;12:e0185597 pubmed publisher
    ..p16 immunohistochemistry is used to evaluate for HPV-associated cervical intraepithelial neoplasia. The diagnostic performance of p16 in HIV infection is unclear...
  29. Friedman M, Lee K, Kim H, Lee I, Kozukue N. Anticarcinogenic effects of glycoalkaloids from potatoes against human cervical, liver, lymphoma, and stomach cancer cells. J Agric Food Chem. 2005;53:6162-9 pubmed
    ..The decreases in cell populations were also observed visually by reversed-phase microscopy. The results complement related observations on the anticarcinogenic potential of food ingredients. ..
  30. Liman A, Giampoli E, Bonfiglio T. Should women with atypical squamous cells, cannot exclude high-grade squamous intraepithelial lesion, receive reflex human papillomavirus-DNA testing?. Cancer. 2005;105:457-60 pubmed
    ..The objective of this pilot study was to evaluate whether reflex human papillomavirus (HPV)-DNA testing performed on smears diagnosed as ASC-H may obviate the need for immediate colposcopic examination...
  31. Beaudenon S, Huibregtse J. HPV E6, E6AP and cervical cancer. BMC Biochem. 2008;9 Suppl 1:S4 pubmed publisher
    ..PUBLICATION HISTORY : Republished from Current BioData's Targeted Proteins database (TPdb; http://www.targetedproteinsdb.com). ..
  32. Munagala R, Donà M, Rai S, Jenson A, Bala N, Ghim S, et al. Significance of multiple HPV infection in cervical cancer patients and its impact on treatment response. Int J Oncol. 2009;34:263-71 pubmed
    ..005). Hence, patients with multiple infections, large tumor size, and HPV 58 and/or 18, are at risk of treatment failure and need to be followed for response and suitable inter-ventions done for a favorable outcome. ..
  33. Licht A, Murphy J, Hyland A, Fix B, Hawk L, Mahoney M. Is use of the human papillomavirus vaccine among female college students related to human papillomavirus knowledge and risk perception?. Sex Transm Infect. 2010;86:74-8 pubmed publisher
    ..These findings suggest knowledge deficits and misperceptions about HPV risk as potential themes for educational campaigns encouraging the greater use of the preventive HPV vaccine among this subgroup. ..
  34. Bili A, Schroeder L, Ledwich L, Kirchner H, Newman E, Wasko M. Patterns of preventive health services in rheumatoid arthritis patients compared to a primary care patient population. Rheumatol Int. 2011;31:1159-65 pubmed publisher
    ..The RA patients with traditional cardiovascular risk factors are more likely to be tested for dyslipidemia. Further work is warranted to improve testing for modifiable CVD risk factors in this group with multiple co-morbidities. ..
  35. Vesco K, Whitlock E, Eder M, Burda B, Senger C, Lutz K. Risk factors and other epidemiologic considerations for cervical cancer screening: a narrative review for the U.S. Preventive Services Task Force. Ann Intern Med. 2011;155:698-705, W216 pubmed publisher
    ..Further reductions in the burden of cervical cancer in older women are probably best achieved by focusing on screening those who have not been adequately screened. ..
  36. Gondi V, Bentzen S, Sklenar K, Dunn E, Petereit D, Tannehill S, et al. Severe late toxicities following concomitant chemoradiotherapy compared to radiotherapy alone in cervical cancer: an inter-era analysis. Int J Radiat Oncol Biol Phys. 2012;84:973-82 pubmed publisher
    ..Other predictive factors include dilator compliance for severe vaginal late toxicity and age for severe vaginal and skeletal late toxicities. ..
  37. Jin X, Lipold L, Sikon A, Rome E. Human papillomavirus vaccine: safe, effective, underused. Cleve Clin J Med. 2013;80:49-60 pubmed publisher
    ..We review the host immune response, the data behind the recommendations for HPV vaccination, and the challenges of implementing the vaccination program. ..
  38. Lor M, Khang P, Xiong P, Moua K, Lauver D. Understanding Hmong women's beliefs, feelings, norms, and external conditions about breast and cervical cancer screening. Public Health Nurs. 2013;30:420-8 pubmed publisher
    ..Findings could guide nursing and public health interventions to improve culturally sensitive, cancer screening for Hmong women. ..
  39. Vanderpool R, Jones M, Stradtman L, Smith J, Crosby R. Self-collecting a cervico-vaginal specimen for cervical cancer screening: an exploratory study of acceptability among medically underserved women in rural Appalachia. Gynecol Oncol. 2014;132 Suppl 1:S21-5 pubmed publisher
    ..Tailoring alternative cancer screening strategies to meet the complex needs of rural women is likely to lead to reductions in cervical cancer incidence and mortality among this vulnerable population. ..
  40. Bosch F, Broker T, Forman D, Moscicki A, Gillison M, Doorbar J, et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013;31 Suppl 5:F1-31 pubmed publisher
    ..Additional details on each subtopic and full information regarding the supporting literature references may be found in the original chapters. ..
  41. Belinson J, Pan Q, Biscotti C, Wu L, Pretorius R, Li L, et al. Primary screening with liquid-based cytology in an unscreened population in rural China, with an emphasis on reprocessing unsatisfactory samples. Acta Cytol. 2002;46:470-4 pubmed
    ..15% (3/1,997). Reprocessing effectively recovers ThinPrep samples otherwise unsatisfactory due to blood and mucus. The ThinPrep Pap test is a highly sensitive screening test when used in a high-risk, unscreened population. ..
  42. Xu W, Dowd B, Abraham J. Lessons from state mandates of preventive cancer screenings. Eur J Health Econ. 2016;17:203-15 pubmed publisher
    ..These results suggest that coverage of preventive care may transfer resources from more advantaged individuals to less advantaged individuals. ..
  43. Lele S, Piver M. Weekly cisplatin induction chemotherapy in the treatment of recurrent cervical carcinoma. Gynecol Oncol. 1989;33:6-8 pubmed
    ..Consolidation therapy with cisplatin combinations administered on a monthly basis did not enhance response to cisplatin. Cisplatin induction therapy was well tolerated with minimal toxicity. ..
  44. Bellinger J, Brandt H, Hardin J, Bynum S, Sharpe P, Jackson D. The role of family history of cancer on cervical cancer screening behavior in a population-based survey of women in the Southeastern United States. Womens Health Issues. 2013;23:e197-204 pubmed publisher
    ..FHC and cervical cancer screening associations were not detected in the sample. Findings suggest targeting older women with screening recommendations and providing available screening resources for underserved women. ..
  45. Harper D, Demars L. HPV vaccines - A review of the first decade. Gynecol Oncol. 2017;146:196-204 pubmed publisher
    ..This simplifies and makes less expensive future comparative studies between existing and new generic vaccines. ..
  46. Munagala R, Kausar H, Munjal C, Gupta R. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and upregulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis. 2011;32:1697-705 pubmed publisher
    ..Together, our data suggest that WA can be exploited as a potent therapeutic agent for the treatment and prevention of cervical cancer without deleterious effects. ..
  47. Wang N, Emancipator S, Rose P, Rodriguez M, Abdul Karim F. Histologic follow-up of atypical endocervical cells. Liquid-based, thin-layer preparation vs. conventional Pap smear. Acta Cytol. 2002;46:453-7 pubmed
    ..Subclassifying AGUS-EC as "favor reactive" or "favor neoplastic" may provide valuable information for directing patient follow-up. ..
  48. Weed J, Graff A, Shoup B, Tawfik O. Small cell undifferentiated (neuroendocrine) carcinoma of the uterine cervix. J Am Coll Surg. 2003;197:44-51 pubmed
    ..Present therapy has not significantly improved outcomes. Tumor lysis syndrome is a possible risk when treating these patients. ..
  49. Waggoner S, Darcy K, Fuhrman B, Parham G, Lucci J, Monk B, et al. Association between cigarette smoking and prognosis in locally advanced cervical carcinoma treated with chemoradiation: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;103:853-8 pubmed
    ..01-2.27; P=0.04) and cotinine-derived smokers (HR: 1.57; 95% CI: 1.03-2.38; P=0.04). Smoking predicts worse overall survival in women with locally advanced cervical carcinoma treated with chemoradiation. ..
  50. Cook R, Zhang J, Mullins J, Kauf T, Brumback B, Steingraber H, et al. Factors associated with initiation and completion of human papillomavirus vaccine series among young women enrolled in Medicaid. J Adolesc Health. 2010;47:596-9 pubmed publisher
  51. Rose P, Sill M, McMeekin D, Ahmed A, Salani R, Yamada S, et al. A phase I study of concurrent weekly topotecan and cisplatin chemotherapy with whole pelvic radiation therapy in locally advanced cervical cancer: a gynecologic oncology group study. Gynecol Oncol. 2012;125:158-62 pubmed publisher
    ..Further expansion of the feasibility cohort of this study was suspended based on the results of a phase 3 trial comparing the efficacy of platinum combinations in advanced and recurrent cervical cancer. ..
  52. Paskett E, Krok Schoen J, Pennell M, Tatum C, Reiter P, Peng J, et al. Results of a Multilevel Intervention Trial to Increase Human Papillomavirus (HPV) Vaccine Uptake among Adolescent Girls. Cancer Epidemiol Biomarkers Prev. 2016;25:593-602 pubmed publisher
    ..g., reminders, automated prompts) may be needed. Cancer Epidemiol Biomarkers Prev; 25(4); 593-602. ©2016 AACR SEE ALL ARTICLES IN THIS CEBP FOCUS SECTION, "MULTILEVEL APPROACHES TO ADDRESSING CANCER HEALTH DISPARITIES". ..
  53. Nida D, Rahman M, Carlson K, Richards Kortum R, Follen M. Fluorescent nanocrystals for use in early cervical cancer detection. Gynecol Oncol. 2005;99:S89-94 pubmed
    ..Combined with optical imaging technologies, quantum dots can help visualize changes in cervical cancer at the molecular level. This ability may alert health care providers to the need for intervention before a cancer can metastasize. ..
  54. Reiter P, Katz M, Paskett E. HPV vaccination among adolescent females from Appalachia: implications for cervical cancer disparities. Cancer Epidemiol Biomarkers Prev. 2012;21:2220-30 pubmed publisher
    ..We determined HPV vaccine coverage among adolescent females from Appalachia, made comparisons to non-Appalachian females, and examined how coverage differs across subregions within Appalachia...
  55. Nag S, Dally M, de la Torre M, Tatsuzaki H, Kizilbash N, Kurusun S, et al. Recommendations for implementation of high dose rate 192Ir brachytherapy in developing countries by the Advisory Group of International Atomic Energy Agency. Radiother Oncol. 2002;64:297-308 pubmed
    ..Intangible benefits of source safety, personnel safety, and easy adaptation to fluctuating demand for treatments also require consideration when evaluating the need to introduce this treatment system. ..
  56. Nag S. High dose rate brachytherapy: its clinical applications and treatment guidelines. Technol Cancer Res Treat. 2004;3:269-87 pubmed
    ..The development of well-controlled randomized trials addressing issues of efficacy, toxicity, quality of life, and costs-versus-benefits will ultimately define the role of HDR brachytherapy in the therapeutic armamentarium. ..
  57. Li X, Zhou L, Feng Y, Abdul Karim F, Gorodeski G. The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev. 2006;15:1906-13 pubmed
    ..b) The data suggest that tissue P2X(7) mRNA and protein levels could be used as a novel biomarker to differentiate normal and cancer uterine epithelial tissues. ..
  58. Zhang Z, Knobloch T, Seamon L, Stoner G, Cohn D, Paskett E, et al. A black raspberry extract inhibits proliferation and regulates apoptosis in cervical cancer cells. Gynecol Oncol. 2011;123:401-6 pubmed publisher
    ..Black raspberries and their bioactive components represent promising candidates for future phytochemical-based mechanistic pathway-targeted cancer prevention strategies. ..
  59. Ansari K, Kasiri S, Mandal S. Histone methylase MLL1 has critical roles in tumor growth and angiogenesis and its knockdown suppresses tumor growth in vivo. Oncogene. 2013;32:3359-70 pubmed publisher
    ..Overall, our studies demonstrated that MLL1 is a key factor in hypoxia signaling, vasculogenesis and tumor growth, and its depletion suppresses tumor growth in vivo, indicating its potential in novel cancer therapy. ..
  60. Schoenberg N, Studts C, Hatcher Keller J, Buelt E, Adams E. Patterns and determinants of breast and cervical cancer non-screening among Appalachian women. Women Health. 2013;53:552-71 pubmed publisher
    ..An improved understanding of cancer screening patterns plus the barriers underlying lack of screening may move researchers closer to developing effective interventions that facilitate women's use of screening. ..
  61. Katz M, Young G, Reiter P, Battaglia T, Wells K, Sanders M, et al. Barriers reported among patients with breast and cervical abnormalities in the patient navigation research program: impact on timely care. Womens Health Issues. 2014;24:e155-62 pubmed publisher
    ..Having a barrier resulted in a delay in diagnostic resolution of an abnormal screening test or clinical finding. Health care systems can use these findings to improve existing PN programs or when developing new programs. ..
  62. Rizou N, Moris D, Pikoulis E, Dimitrokallis N, Mpaili E, Felekouras E, et al. Minimally Invasive Lymphadenectomy in Uterine Cervical Cancer: A Systematic Review. Anticancer Res. 2017;37:335-342 pubmed
    ..Multicentre randomized controlled trials investigating its long-term oncological outcomes and its cost-effectiveness are required to determine the advantages of this procedure over the open approach in cervical cancer. ..
  63. Casey B, Crosby R, Vanderpool R, Dignan M, Bates W. Predictors of initial uptake of human papillomavirus vaccine uptake among rural Appalachian young women. J Prim Prev. 2013;34:71-80 pubmed publisher
    ..HPV vaccine interventions may benefit from highlighting paternal endorsement, healthcare provider recommendation, and peer support. ..
  64. Andresen E, Peterson Besse J, Krahn G, Walsh E, Horner Johnson W, Iezzoni L. Pap, mammography, and clinical breast examination screening among women with disabilities: a systematic review. Womens Health Issues. 2013;23:e205-14 pubmed publisher
    ..This information is essential for national and local public health and health care organizations to target interventions to improve care for women with disabilities. ..
  65. Phaeton R, Jiang Z, Revskaya E, Fisher D, Goldberg G, Dadachova E. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer. Cancer Med. 2016;5:9-16 pubmed publisher
    ..Thus, both of these radionuclides are candidates for the clinical trials of this approach in patients with advanced, recurrent or metastatic cervical cancer. ..
  66. Rose P, Fusco N, Smrekar M, Mossbruger K, Rodriguez M. Successful administration of carboplatin in patients with clinically documented carboplatin hypersensitivity. Gynecol Oncol. 2003;89:429-33 pubmed
    ..A prolonged desensitizing carboplatin infusion regimen is tolerated in the majority of patients with clinically documented moderate-severe carboplatin hypersensitivity. Objective response rates seem acceptable with this schedule. ..
  67. Galloway D. Papillomavirus vaccines in clinical trials. Lancet Infect Dis. 2003;3:469-75 pubmed
  68. Kunos C, Radivoyevitch T, Pink J, Chiu S, Stefan T, JACOBBERGER J, et al. Ribonucleotide reductase inhibition enhances chemoradiosensitivity of human cervical cancers. Radiat Res. 2010;174:574-81 pubmed publisher
    ..We conclude that blockage of RNR activity by 3-AP impairs DNA damage responses that rely on deoxyribonucleotide production and thereby may substantially increase chemoradiosensitivity of human cervical cancers. ..
  69. Kunos C, Colussi V, Pink J, Radivoyevitch T, Oleinick N. Radiosensitization of human cervical cancer cells by inhibiting ribonucleotide reductase: enhanced radiation response at low-dose rates. Int J Radiat Oncol Biol Phys. 2011;80:1198-204 pubmed publisher
    ..We conclude that RNR inhibition by 3-AP impedes DNA damage repair mechanisms that rely on deoxyribonucleotide production and thereby increases radiation sensitivity of human cervical cancers to low-dose-rate radiation. ..
  70. Ramaswamy M, Kelly P, Koblitz A, Kimminau K, Engelman K. Understanding the role of violence in incarcerated women's cervical cancer screening and history. Women Health. 2011;51:423-41 pubmed publisher
    ..This study highlights the heightened cervical cancer risk experienced by women with criminal justice histories and suggests that violence at several levels has implications for cervical cancer prevention for these women. ..
  71. Xi L, Jiang M, Shen Z, Hulbert A, Zhou X, Lin Y, et al. Inverse association between methylation of human papillomavirus type 16 DNA and risk of cervical intraepithelial neoplasia grades 2 or 3. PLoS ONE. 2011;6:e23897 pubmed publisher
    ..Results suggest that degree of the viral genome methylation is related to the outcome of an HPV16 cervical infection. ..
  72. Kim J, Campos N, O Shea M, Diaz M, Mutyaba I. Model-based impact and cost-effectiveness of cervical cancer prevention in sub-Saharan Africa. Vaccine. 2013;31 Suppl 5:F60-72 pubmed publisher
    ..Updates of the progress in the field are presented in a separate monograph entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012. ..
  73. He C, Mao D, Hua G, Lv X, Chen X, Angeletti P, et al. The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression. EMBO Mol Med. 2015;7:1426-49 pubmed publisher
    ..Our study indicates that combined targeting of the Hippo and the ERBB signaling pathways represents a novel therapeutic strategy for prevention and treatment of cervical cancer. ..
  74. Landen C, Mathur S, Richardson M, Creasman W. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003;188:1174-6 pubmed
    ..001). In this cohort, COX-2 expression is significantly more common in endometrial adenocarcinoma and ovarian serous cystadenocarcinoma, but not in cervical squamous carcinoma, compared with normal tissue. ..
  75. Blair A, Casas C. Gynecologic cancers. Prim Care. 2009;36:115-30, ix pubmed publisher
    ..In this article, the epidemiology, screening guidelines, and a review of management are presented for vulvar, cervical, ovarian, and endometrial cancer. ..
  76. Mayr N, Wang J, Zhang D, Montebello J, Grecula J, Lo S, et al. Synergistic effects of hemoglobin and tumor perfusion on tumor control and survival in cervical cancer. Int J Radiat Oncol Biol Phys. 2009;74:1513-21 pubmed publisher
    ..The outcome was worst when both were impaired. The management of Hgb may be particularly important in patients with low tumor perfusion. ..
  77. Levinson K, Abuelo C, Salmeron J, Chyung E, Zou J, Belinson S, et al. The Peru Cervical Cancer Prevention Study (PERCAPS): the technology to make screening accessible. Gynecol Oncol. 2013;129:318-23 pubmed publisher
  78. Abdullah N, Laing R, Hariri S, Young C, Schafer S. Use of claims data to estimate annual cervical cancer screening percentages in Portland metropolitan area, Oregon. Cancer Epidemiol. 2016;41:106-12 pubmed publisher
    ..Overall, percentage of women screened in Portland, Oregon fell following changes in screening recommendations released in 2009 and later modified in 2012. ..
  79. Maurer K, Luo H, Shen Z, Wang G, Du H, Wang C, et al. Evaluation of a new solid media specimen transport card for high risk HPV detection and cervical cancer prevention. J Clin Virol. 2016;76:14-9 pubmed publisher
    ..The POI card is suitable for DNA transport and HR-HPV testing. This card has the potential to make cervical cancer screening programs more affordable worldwide. ..
  80. Chegini N, Zhao Y, McLean F. Expression of messenger ribonucleic acid and presence of immunoreactive proteins for epidermal growth factor (EGF), transforming growth factor alpha (TGF alpha) and EGF/TGF alpha receptors and 125I-EGF binding sites in human fallopian tube. Biol Reprod. 1994;50:1049-58 pubmed
    ..The results imply the importance of EGF/TGF alpha in a variety of tubal biochemical and physiological functions and possibly early embryonic development. ..
  81. Laitman C. DES exposure and the aging woman: mothers and daughters. Curr Womens Health Rep. 2002;2:390-3 pubmed
    ..DES mothers have an increased risk of breast cancer (RR = 1.3). DES sons have an increased prevalence of urogenital anomalies, and a possible increased risk of testicular cancer. ..
  82. Piyathilake C, Azrad M, Macaluso M, Johanning G, Cornwell P, Partridge E, et al. Protective association of MTHFR polymorphism on cervical intraepithelial neoplasia is modified by riboflavin status. Nutrition. 2007;23:229-35 pubmed
    ..The practical implications of this complex gene-nutrient-disease interaction will require further investigation. ..
  83. McAlearney A, Oliveri J, Post D, Song P, Jacobs E, Waibel J, et al. Trust and distrust among Appalachian women regarding cervical cancer screening: a qualitative study. Patient Educ Couns. 2012;86:120-6 pubmed publisher
  84. Garcia F, Cornelison T, Nuno T, Greenspan D, Byron J, Hsu C, et al. Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia. Gynecol Oncol. 2014;132:377-82 pubmed publisher
    ..Further studies may be necessary to better delineate the risk factors for persistent HPV infection and biology of the disease to facilitate the evaluation of chemopreventive strategies. ..
  85. Shai A, Pitot H, Lambert P. p53 Loss synergizes with estrogen and papillomaviral oncogenes to induce cervical and breast cancers. Cancer Res. 2008;68:2622-31 pubmed publisher
    ..These data show the importance of the synergy between estrogen and p53 insufficiency in determining basic properties of carcinogenesis in hormone-responsive tissues, such as the breast and the reproductive tract. ..
  86. Chen L, Yang B. Assessment of reflex human papillomavirus DNA testing in patients with atypical endocervical cells on cervical cytology. Cancer. 2008;114:236-41 pubmed publisher
    ..0%) and high specificity (91.2%) in detecting significant cervical lesions, reflex HPV testing for cytologic diagnosis of AEC appears to be a useful ancillary tool in the selection of high-risk patients for colposcopy. ..
  87. Maufort J, Shai A, Pitot H, Lambert P. A role for HPV16 E5 in cervical carcinogenesis. Cancer Res. 2010;70:2924-31 pubmed publisher
    ..Prolonged treatment of E5 transgenic mice with exogenous estrogen uncovered an ability of E5 to cause frank cancer. These data indicate that E5 acts as an oncogene in the reproductive tracts of female mice. ..
  88. Cho J, Cho C, Kao C, Chen C, Tseng C, Lee Y, et al. Crude aqueous extracts of Pluchea indica (L.) Less. inhibit proliferation and migration of cancer cells through induction of p53-dependent cell death. BMC Complement Altern Med. 2012;12:265 pubmed publisher
    ..indica root. The in vitro anti-cancer effects of crude aqueous extracts of P. indica leaf and root indicate that it has sufficient potential to warrant further examination and development as a new anti-cancer agent. ..
  89. Gonzales K, Harding A, Lambert W, Fu R, Henderson W. Perceived experiences of discrimination in health care: a barrier for cancer screening among American Indian women with type 2 diabetes. Womens Health Issues. 2013;23:e61-7 pubmed publisher
    ..More research is needed among AIs to examine features of health care systems related to the phenomenon patients perceived experience of discrimination. ..
  90. Maruyama Y, van Nagell J, Yoneda J, Donaldson E, Gallion H, Higgins R, et al. Efficacy of brachytherapy with californium-252 neutrons versus cesium-137 photons for eradication of bulky localized cervical cancer: single-institution study. J Natl Cancer Inst. 1988;80:501-6 pubmed
    ..0 for 252Cf...
  91. Shin M, Balsitis S, Brake T, Lambert P. Human papillomavirus E7 oncoprotein overrides the tumor suppressor activity of p21Cip1 in cervical carcinogenesis. Cancer Res. 2009;69:5656-63 pubmed publisher
    ..Taken together, we conclude that p21(Cip1) functions as a tumor suppressor in cervical carcinogenesis and that p21(Cip1) inactivation by HPV-16 E7 partially contributes to the contribution of E7 to cervical carcinogenesis. ..
  92. Shamanna R, Hoque M, PE ERY T, Mathews M. Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. Oncogene. 2013;32:5176-85 pubmed publisher
    ..We conclude that high-risk strains of HPV utilize the cellular NF90/NF45 complex for viral E6 expression in infected cervical carcinoma cell lines. Interference with NF90/NF45 function could assist in controlling cervical carcinoma. ..